Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen Reports Fiscal 2024 Third Quarter Financial Results
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
Vistagen to Present at Stifel 2023 Healthcare Conference
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Vistagen Announces Pricing of $100 Million Underwritten Offering